Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy. In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Avelumab is indicated, in combination with axitinib, for the first-line treatment of advanced renal cell carcinoma (RCC).
University of Washington, Seattle, Washington, United States
University of Chicago, Chicago, Illinois, United States
START Midwest, Grand Rapids, Michigan, United States
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California San Francisco, San Francisco, California, United States
Radboud University, Nijmegen, Netherlands
Sung Yong Oh, Busan, Korea, Republic of
Fondazione del Piemonte per l'Oncologia, Candiolo, Italy
Istituto Nazionale Tumori, MIlano, Italy
AOU Policlinico Federico II, Napoli, Italy
Univeristy of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Penn State Cancer Intsitute, Hershey, Pennsylvania, United States
Ben Taub General Hospital, Houston, Texas, United States
Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
Michael E. DeBakey Veteran Affairs Medical Center, Houston, Texas, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University College Hospital, London, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.